Great West Life Assurance Co. Can Has $2 Million Holdings in Intellia Therapeutics Inc (NTLA)

Share on StockTwits

Great West Life Assurance Co. Can raised its stake in Intellia Therapeutics Inc (NASDAQ:NTLA) by 6,659.7% in the first quarter, HoldingsChannel reports. The firm owned 94,636 shares of the company’s stock after acquiring an additional 93,236 shares during the quarter. Great West Life Assurance Co. Can’s holdings in Intellia Therapeutics were worth $1,995,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. MetLife Investment Advisors LLC bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $146,000. Slow Capital Inc. bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $294,000. D.A. Davidson & CO. bought a new position in Intellia Therapeutics in the fourth quarter valued at approximately $323,000. Cim Investment Mangement Inc. bought a new position in Intellia Therapeutics in the first quarter valued at approximately $458,000. Finally, California State Teachers Retirement System grew its stake in Intellia Therapeutics by 12.5% in the fourth quarter. California State Teachers Retirement System now owns 26,272 shares of the company’s stock valued at $505,000 after purchasing an additional 2,929 shares in the last quarter. Hedge funds and other institutional investors own 60.74% of the company’s stock.

In other news, insider John M. Leonard sold 8,400 shares of the firm’s stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $24.00, for a total value of $201,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jean Francois Formela sold 39,245 shares of the firm’s stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total value of $936,778.15. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 54,331 shares of company stock valued at $1,305,796. Insiders own 12.80% of the company’s stock.

A number of research analysts have weighed in on NTLA shares. TheStreet upgraded Intellia Therapeutics from a “d” rating to a “c-” rating in a research note on Monday, March 19th. ValuEngine upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 12th. Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Intellia Therapeutics in a research note on Thursday, March 15th. JMP Securities started coverage on Intellia Therapeutics in a research note on Thursday, March 8th. They issued an “outperform” rating for the company. Finally, Leerink Swann restated an “outperform” rating on shares of Intellia Therapeutics in a research note on Wednesday, March 14th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Intellia Therapeutics has a consensus rating of “Buy” and an average target price of $34.83.

NTLA opened at $27.39 on Friday. Intellia Therapeutics Inc has a 12-month low of $12.12 and a 12-month high of $35.99. The company has a market capitalization of $1.12 billion, a PE ratio of -14.57 and a beta of 3.21.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Tuesday, May 1st. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.07. Intellia Therapeutics had a negative return on equity of 31.80% and a negative net margin of 278.64%. The company had revenue of $7.47 million during the quarter, compared to analysts’ expectations of $6.14 million. sell-side analysts anticipate that Intellia Therapeutics Inc will post -2 EPS for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Gap Inc  Expected to Announce Quarterly Sales of $3.98 Billion
Gap Inc Expected to Announce Quarterly Sales of $3.98 Billion
Sinovac Biotech  Given Daily Media Impact Rating of -0.02
Sinovac Biotech Given Daily Media Impact Rating of -0.02
Limoneira  Receives Daily News Sentiment Rating of 0.06
Limoneira Receives Daily News Sentiment Rating of 0.06
Motorola Solutions  Hits New 1-Year High at $121.69
Motorola Solutions Hits New 1-Year High at $121.69
Vince  Hits New 52-Week High at $20.35
Vince Hits New 52-Week High at $20.35
Brokerages Anticipate First Industrial Realty Trust, Inc.  Will Post Earnings of $0.40 Per Share
Brokerages Anticipate First Industrial Realty Trust, Inc. Will Post Earnings of $0.40 Per Share


© 2006-2018 Ticker Report. Google+.